Noel Smith, Ph.D., Head of Immunology at Lonza recently presented the webinar The good, the bad, and the ugly: How does identifying and mitigating potential for immunogenicity and immunotoxicity de-risk and accelerate your drug development? In it, Dr. Smith discussed how to overcome challenges with immunogenicity and immunotoxicity assessments in drug development and what tools are available to do so. He also reviewed case studies highlighting effective immunosafety assays as well as Lonza’s success in utilizing them as they apply their experience to help guide their clients’ drug candidates to FIH studies. The Q&A below offers additional insight from Dr. Smith on common questions about this topic as well as addressing several questions asked during a discussion after the webinar.
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center